Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:desferrioxamine B
go back to main search page
Accession:CHEBI:4356 term browser browse the term
Definition:An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Synonyms:exact_synonym: N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide
 related_synonym: DFO;   DFOB;   Deferoxamin;   Deferrioxamine;   Desferrioxamine;   Formula=C25H48N6O8;   InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);   InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N;   N(4)-{5-[acetyl(hydroxy)amino]pentyl}-N(1)-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N(1)-hydroxybutanediamide;   SMILES=CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN;   deferoxamina;   deferoxamine;   deferoxaminum;   deferrioxamine B
 xref: Beilstein:2514118;   CAS:70-51-9;   Chemspider:2867;   DrugBank:DB00746;   Drug_Central:792;   HMDB:HMDB0014884;   KEGG:C06940;   KEGG:D03670;   LINCS:LSM-6541;   LIPID_MAPS_instance:LMFA08020169
 xref_mesh: MESH:D003676
 xref: PMID:11239825;   PMID:18536609;   PMID:28156129;   PMID:28285915;   PMID:28318697;   PMID:28455567;   PMID:29182270;   PMID:30701380;   PMID:31035197;   PMID:31229836;   PMID:31846315;   PMID:32039778;   PMID:32572744;   PMID:32734456;   PMID:32856363;   PMID:33784308;   Patent:BE609053;   Wikipedia:Deferoxamine
 cyclic_relationship: is_conjugate_acid_of CHEBI:84700;   is_conjugate_base_of CHEBI:195191


show annotations for term's descendants           Sort by:
desferrioxamine B term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACO1 aconitase 1 increases activity
increases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in increased activity of ACO1 protein
Deferoxamine results in increased expression of ACO1 protein
[Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein		 CTD PMID:10397746 PMID:11054110 PMID:15893546 PMID:16568477 PMID:18073202 More... NCBI chr 9:32,384,643...32,454,769
Ensembl chr 9:32,384,603...32,454,769 		JBrowse link
G ACO2 aconitase 2 decreases expression ISO Deferoxamine results in decreased expression of ACO2 protein CTD PMID:16568477 PMID:17469137 NCBI chr22:41,469,117...41,528,974
Ensembl chr22:41,447,830...41,529,273 		JBrowse link
G ACP5 acid phosphatase 5, tartrate resistant multiple interactions
decreases activity		 ISO Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein] CTD PMID:31238089 NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993 		JBrowse link
G ACSL4 acyl-CoA synthetase long chain family member 4 multiple interactions EXP Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA] CTD PMID:36843388 NCBI chr  X:109,641,335...109,733,257
Ensembl chr  X:109,624,244...109,733,403 		JBrowse link
G ACTA2 actin alpha 2, smooth muscle decreases expression
multiple interactions
increases expression		 ISO
EXP		 Deferoxamine results in decreased expression of ACTA2 protein
Deferoxamine inhibits the reaction [Artesunate results in decreased expression of ACTA2 mRNA]
Deferoxamine results in increased expression of ACTA2 mRNA		 CTD PMID:18032466 PMID:30551460 NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339 		JBrowse link
G ADM adrenomedullin increases expression EXP Deferoxamine results in increased expression of ADM mRNA CTD PMID:11754965 NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions ISO
EXP		 Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased phosphorylation of AKT1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of AKT1 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA]		 CTD PMID:18032466 PMID:34577062 PMID:35690295 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751 		JBrowse link
G ALDH3A1 aldehyde dehydrogenase 3 family member A1 decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of ALDH3A1 mRNA
Deferoxamine inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]		 CTD PMID:14645679 NCBI chr17:19,737,984...19,748,298
Ensembl chr17:19,737,984...19,748,943 		JBrowse link
G ALPL alkaline phosphatase, biomineralization associated decreases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in decreased expression of ALPL mRNA
Indomethacin promotes the reaction [Deferoxamine results in decreased expression of ALPL protein]; Sulindac promotes the reaction [Deferoxamine results in decreased expression of ALPL protein]		 CTD PMID:16772336 PMID:21882223 NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410 		JBrowse link
G ANXA3 annexin A3 multiple interactions
decreases expression		 EXP ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ANXA3 protein]
Deferoxamine results in decreased expression of ANXA3 protein		 CTD PMID:19515424 NCBI chr 4:78,551,770...78,610,447
Ensembl chr 4:78,551,747...78,610,451 		JBrowse link
G APAF1 apoptotic peptidase activating factor 1 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA] CTD PMID:33962019 PMID:35690295 NCBI chr12:98,645,290...98,735,433
Ensembl chr12:98,645,290...98,735,433 		JBrowse link
G APP amyloid beta precursor protein affects binding
multiple interactions		 EXP Deferoxamine binds to APP 5' UTR
[Deferoxamine binds to APP 5' UTR] which results in decreased expression of APP protein; [Deferoxamine binds to APP 5' UTR] which results in decreased secretion of APP protein modified form; Deferoxamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]		 CTD PMID:15681799 PMID:17964426 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128 		JBrowse link
G AQP4 aquaporin 4 multiple interactions ISO Deferoxamine inhibits the reaction [manganese(III) acetate dihydrate results in increased expression of AQP4 protein] CTD PMID:20648640 NCBI chr18:26,852,038...26,865,803
Ensembl chr18:26,852,043...26,865,771 		JBrowse link
G ARHGDIA Rho GDP dissociation inhibitor alpha decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of ARHGDIA protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ARHGDIA protein]		 CTD PMID:19515424 NCBI chr17:81,867,721...81,871,337
Ensembl chr17:81,867,721...81,871,378 		JBrowse link
G ARNT aryl hydrocarbon receptor nuclear translocator increases activity
multiple interactions
increases expression		 ISO
EXP		 Deferoxamine results in increased activity of ARNT protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA]
Deferoxamine results in increased expression of ARNT mRNA		 CTD PMID:10559391 PMID:33962019 PMID:35690295 NCBI chr 1:150,809,713...150,876,599
Ensembl chr 1:150,809,713...150,876,708 		JBrowse link
G ASH2L ASH2 like, histone lysine methyltransferase complex subunit increases expression
affects expression		 EXP Deferoxamine results in increased expression of ASH2L mRNA
Deferoxamine affects the expression of ASH2L mRNA		 CTD PMID:23483119 NCBI chr 8:38,105,493...38,140,080
Ensembl chr 8:38,105,493...38,144,076 		JBrowse link
G ATF1 activating transcription factor 1 increases activity ISO Deferoxamine results in increased activity of ATF1 protein CTD PMID:10559391 NCBI chr12:50,763,459...50,821,162
Ensembl chr12:50,763,710...50,821,162 		JBrowse link
G ATM ATM serine/threonine kinase multiple interactions EXP Deferoxamine results in increased phosphorylation of and results in increased activity of ATM protein CTD PMID:16959548 NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,823...108,369,102 		JBrowse link
G ATP6V0D2 ATPase H+ transporting V0 subunit d2 multiple interactions
affects expression		 ISO Deferoxamine affects the reaction [TF protein affects the expression of ATP6V0D2 mRNA]; TF protein affects the reaction [Deferoxamine affects the expression of ATP6V0D2 mRNA] CTD PMID:31238089 NCBI chr 8:86,098,910...86,154,225
Ensembl chr 8:85,987,323...86,154,225 		JBrowse link
G ATP7A ATPase copper transporting alpha increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of ATP7A mRNA
cupric chloride promotes the reaction [Deferoxamine results in increased expression of ATP7A mRNA]; Deferoxamine promotes the reaction [cupric chloride results in increased expression of ATP7A protein]		 CTD PMID:23174565 NCBI chr  X:77,910,693...78,050,395
Ensembl chr  X:77,910,690...78,050,395 		JBrowse link
G BAK1 BCL2 antagonist/killer 1 multiple interactions EXP [Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA] CTD PMID:33962019 NCBI chr 6:33,572,552...33,580,276
Ensembl chr 6:33,572,547...33,580,293 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 EXP
ISO		 Deferoxamine results in increased expression of BAX mRNA; Deferoxamine results in increased expression of BAX protein
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of BAX mRNA]
[Cisplatin co-treated with Deferoxamine] results in increased expression of BAX protein; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX protein; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of BAX protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; TP53 protein affects the reaction [Deferoxamine results in increased expression of BAX protein]		 CTD PMID:16800926 PMID:21742779 PMID:33962019 PMID:34126102 PMID:34577062 More... NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BBC3 BCL2 binding component 3 multiple interactions
increases expression		 EXP [Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA]
Deferoxamine results in increased expression of BBC3 mRNA		 CTD PMID:33962019 NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766 		JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions
decreases expression		 ISO
EXP		 Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased expression of BCL2 mRNA]; Deferoxamine inhibits the reaction [Copper Sulfate results in decreased expression of BCL2 mRNA]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]
Deferoxamine results in decreased expression of BCL2 mRNA		 CTD PMID:30431687 PMID:33962019 PMID:34577062 PMID:35690295 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BCL2L15 BCL2 like 15 multiple interactions
increases expression		 EXP [Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA]
Deferoxamine results in increased expression of BCL2L15 mRNA		 CTD PMID:33962019 NCBI chr 1:113,876,816...113,887,581
Ensembl chr 1:113,876,816...113,887,581 		JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions ISO Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of BDNF protein] CTD PMID:34577062 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058 		JBrowse link
G BECN1 beclin 1 multiple interactions EXP Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of BECN1 protein]; Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of BECN1 protein] CTD PMID:21742779 PMID:32687844 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350 		JBrowse link
G BID BH3 interacting domain death agonist multiple interactions EXP [Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA] CTD PMID:33962019 NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770 		JBrowse link
G BMP6 bone morphogenetic protein 6 multiple interactions
decreases expression		 EXP Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]
Deferoxamine results in decreased expression of BMP6 mRNA		 CTD PMID:25633564 PMID:32816093 NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728 		JBrowse link
G BNIP3 BCL2 interacting protein 3 increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of BNIP3 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA]		 CTD PMID:33962019 NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967 		JBrowse link
G BNIP3L BCL2 interacting protein 3 like increases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in increased expression of BNIP3L mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA]		 CTD PMID:11832486 PMID:33962019 NCBI chr 8:26,383,054...26,413,127
Ensembl chr 8:26,383,054...26,505,636 		JBrowse link
G C5 complement C5 multiple interactions EXP Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased cleavage of C5 protein]; Deferoxamine inhibits the reaction [Asbestos, Serpentine results in increased cleavage of C5 protein] CTD PMID:10777245 NCBI chr 9:120,952,335...121,074,865
Ensembl chr 9:120,932,987...121,075,195 		JBrowse link
G CA2 carbonic anhydrase 2 decreases expression ISO Deferoxamine results in decreased expression of CAR2 mRNA CTD PMID:31238089 NCBI chr 8:85,464,007...85,481,493
Ensembl chr 8:85,463,968...85,481,493 		JBrowse link
G CA9 carbonic anhydrase 9 increases expression EXP Deferoxamine results in increased expression of CA9 mRNA CTD PMID:25351418 NCBI chr 9:35,673,928...35,681,159
Ensembl chr 9:35,673,928...35,681,159 		JBrowse link
G CACNA1H calcium voltage-gated channel subunit alpha1 H increases expression ISO Deferoxamine results in increased expression of CACNA1H mRNA CTD PMID:12679337 NCBI chr16:1,153,106...1,221,768
Ensembl chr16:1,153,103...1,224,169 		JBrowse link
G CASP12 caspase 12 (gene/pseudogene) multiple interactions EXP Deferoxamine promotes the reaction [manganese chloride results in increased cleavage of and results in increased activity of CASP12 protein] CTD PMID:23764342 NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670 		JBrowse link
G CASP3 caspase 3 increases expression
multiple interactions
increases activity		 EXP
ISO		 Deferoxamine results in increased expression of CASP3 protein
Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]
Deferoxamine results in increased activity of CASP3 protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Deferoxamine inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Deferoxamine promotes the reaction [manganese chloride results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein]
Deferoxamine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of CASP3 mRNA]; Deferoxamine inhibits the reaction [Copper Sulfate results in increased secretion of CASP3 protein]; Deferoxamine inhibits the reaction [Manganese results in increased activity of CASP3 protein]		 CTD PMID:11933051 PMID:12523938 PMID:16374551 PMID:16800926 PMID:23764342 More... NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CASP8 caspase 8 increases activity
multiple interactions		 EXP Deferoxamine results in increased activity of CASP8 protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein]		 CTD PMID:16374551 PMID:33962019 PMID:35690295 NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836 		JBrowse link
G CASP9 caspase 9 multiple interactions EXP Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased activity of CASP9 protein] CTD PMID:12540492 PMID:14766669 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534 		JBrowse link
G CAT catalase multiple interactions ISO
EXP		 Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased activity of CAT protein]; Deferoxamine inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CAT mRNA		 CTD PMID:22115772 PMID:34577062 PMID:35690295 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CAV1 caveolin 1 increases expression EXP Deferoxamine results in increased expression of CAV1 protein CTD PMID:16927372 NCBI chr 7:116,525,009...116,561,185
Ensembl chr 7:116,524,994...116,561,179 		JBrowse link
G CCL2 C-C motif chemokine ligand 2 multiple interactions ISO Deferoxamine inhibits the reaction [[Lipopolysaccharides co-treated with Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein] CTD PMID:25813056 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208 		JBrowse link
G CCNA2 cyclin A2 decreases expression EXP Deferoxamine results in decreased expression of CCNA2 protein CTD PMID:11468187 NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883 		JBrowse link
G CCNB1 cyclin B1 decreases expression EXP Deferoxamine results in decreased expression of CCNB1 protein CTD PMID:11468187 NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245 		JBrowse link
G CCND1 cyclin D1 decreases expression EXP Deferoxamine results in decreased expression of CCND1 protein CTD PMID:11468187 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G CCND2 cyclin D2 decreases expression EXP Deferoxamine results in decreased expression of CCND2 protein CTD PMID:11468187 NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353 		JBrowse link
G CCND3 cyclin D3 decreases expression EXP Deferoxamine results in decreased expression of CCND3 protein CTD PMID:11468187 NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357 		JBrowse link
G CCNE1 cyclin E1 increases expression EXP Deferoxamine results in increased expression of CCNE1 protein CTD PMID:11468187 NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312 		JBrowse link
G CD36 CD36 molecule (CD36 blood group) decreases expression EXP Deferoxamine results in decreased expression of CD36 protein CTD PMID:24170104 NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277 		JBrowse link
G CDC14A cell division cycle 14A increases expression EXP Deferoxamine results in increased expression of CDC14A mRNA alternative form CTD PMID:16760464 NCBI chr 1:100,345,001...100,520,277
Ensembl chr 1:100,345,001...100,520,277 		JBrowse link
G CDK2 cyclin dependent kinase 2 decreases activity
decreases expression		 EXP Deferoxamine results in decreased activity of CDK2 protein
Deferoxamine results in decreased expression of CDK2 protein		 CTD PMID:11468187 PMID:17631934 NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789 		JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A increases expression
multiple interactions
decreases expression		 EXP
ISO		 Deferoxamine results in increased expression of CDKN1A mRNA; Deferoxamine results in increased expression of CDKN1A protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA]
Deferoxamine results in decreased expression of CDKN1A protein		 CTD PMID:10397746 PMID:10559391 PMID:11468187 PMID:12807743 PMID:16227210 More... NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337 		JBrowse link
G CDKN1B cyclin dependent kinase inhibitor 1B multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1B mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA] CTD PMID:33962019 PMID:35690295 NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369 		JBrowse link
G CKB creatine kinase B multiple interactions ISO [Deferoxamine co-treated with Acetylcysteine] inhibits the reaction [Acetaminophen results in decreased activity of CKB protein]; [Deferoxamine co-treated with Acetylcysteine] inhibits the reaction [Carbon Tetrachloride results in decreased activity of CKB protein] CTD PMID:19688255 NCBI chr14:103,519,667...103,522,830
Ensembl chr14:103,519,667...103,522,833 		JBrowse link
G COL1A1 collagen type I alpha 1 chain multiple interactions ISO Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of COL1A1 mRNA] CTD PMID:11306436 NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632 		JBrowse link
G COX4I1 cytochrome c oxidase subunit 4I1 multiple interactions EXP Deferoxamine inhibits the reaction [EPAS1 protein results in increased degradation of COX4I1 protein] CTD PMID:18515279 NCBI chr16:85,799,695...85,807,068
Ensembl chr16:85,798,633...85,807,068 		JBrowse link
G CP ceruloplasmin multiple interactions EXP Deferoxamine inhibits the reaction [CP protein results in increased oxidation of 3-carboxy-2,2,5,5-tetramethylpyrrolidin-1-yloxyl] CTD PMID:22824865 NCBI chr 3:149,162,414...149,221,829
Ensembl chr 3:149,162,410...149,221,829 		JBrowse link
G CREB1 cAMP responsive element binding protein 1 increases activity ISO Deferoxamine results in increased activity of CREB1 protein CTD PMID:10559391 NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988 		JBrowse link
G CRP C-reactive protein multiple interactions ISO Deferoxamine inhibits the reaction [Copper Sulfate results in increased secretion of CRP protein] CTD PMID:30431687 NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589 		JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions EXP Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CSF2 mRNA] CTD PMID:20801209 PMID:21703343 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170 		JBrowse link
G CTNNB1 catenin beta 1 multiple interactions EXP [Oxygen deficiency co-treated with Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] affects the localization of CTNNB1 protein; Deferoxamine inhibits the reaction [ferumoxides results in increased activity of CTNNB1 protein] CTD PMID:20338187 PMID:34648812 NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096 		JBrowse link
G CTSK cathepsin K multiple interactions
decreases expression		 ISO Deferoxamine inhibits the reaction [TF protein results in increased expression of CTSK mRNA]; TF protein affects the reaction [Deferoxamine results in decreased expression of CTSK mRNA] CTD PMID:31238089 NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,794,880...150,809,577 		JBrowse link
G CXCL2 C-X-C motif chemokine ligand 2 multiple interactions ISO Deferoxamine promotes the reaction [Asbestos, Amphibole results in increased expression of CXCL2] CTD PMID:21605006 NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions
increases expression
increases secretion		 EXP Deferoxamine inhibits the reaction [Coal Ash results in increased expression of CXCL8 protein]; Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CXCL8 mRNA]; Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CXCL8 protein]; Deferoxamine promotes the reaction [Asbestos, Amphibole results in increased expression of CXCL8]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of CXCL8 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased secretion of CXCL8 protein]; KT 5720 inhibits the reaction [Deferoxamine results in increased expression of CXCL8 protein]; rottlerin inhibits the reaction [Deferoxamine results in increased expression of CXCL8 protein] CTD PMID:9344885 PMID:17097691 PMID:20801209 PMID:21605006 PMID:26303504 More... NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYBB cytochrome b-245 beta chain multiple interactions ISO [Deferoxamine co-treated with Benzene] results in increased expression of CYBB protein; Deferoxamine inhibits the reaction [Benzene results in increased expression of CYBB mRNA] CTD PMID:35661779 NCBI chr  X:37,780,059...37,813,461
Ensembl chr  X:37,780,018...37,813,461 		JBrowse link
G CYCS cytochrome c, somatic multiple interactions
increases expression		 EXP [Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA]
Deferoxamine results in increased expression of CYCS mRNA		 CTD PMID:33962019 NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260 		JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 multiple interactions EXP
ISO		 Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA]
Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]		 CTD PMID:10799651 PMID:10823667 PMID:20801209 PMID:21703343 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536 		JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 multiple interactions ISO Deferoxamine inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine] CTD PMID:7710944 NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220 		JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 decreases expression EXP Deferoxamine results in decreased expression of CYP3A4 mRNA; Deferoxamine results in decreased expression of CYP3A4 protein CTD PMID:19695866 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248 		JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP Deferoxamine promotes the reaction [manganese chloride results in increased expression of DDIT3 protein] CTD PMID:23764342 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737 		JBrowse link
G DES desmin increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of DES mRNA
Deferoxamine inhibits the reaction [Artesunate results in decreased expression of DES mRNA]		 CTD PMID:30551460 NCBI chr 2:219,418,377...219,426,734
Ensembl chr 2:219,418,377...219,426,735 		JBrowse link
G DIABLO diablo IAP-binding mitochondrial protein multiple interactions
increases expression		 EXP [Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA]
Deferoxamine results in increased expression of DIABLO mRNA		 CTD PMID:33962019 NCBI chr12:122,207,662...122,227,456
Ensembl chr12:122,207,668...122,226,062 		JBrowse link
G DICER1 dicer 1, ribonuclease III decreases expression EXP Deferoxamine results in decreased expression of DICER1 mRNA; Deferoxamine results in decreased expression of DICER1 protein CTD PMID:25351418 NCBI chr14:95,086,228...95,158,010
Ensembl chr14:95,086,228...95,158,010 		JBrowse link
G DIO2 iodothyronine deiodinase 2 increases activity ISO Deferoxamine results in increased activity of DIO2 protein CTD PMID:17615150 NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,526...80,387,757 		JBrowse link
G DNM1L dynamin 1 like multiple interactions ISO
EXP		 Deferoxamine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]
[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA]		 CTD PMID:26318285 PMID:33962019 NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650 		JBrowse link
G DNMT1 DNA methyltransferase 1 increases expression
decreases expression		 EXP Deferoxamine results in increased expression of DNMT1 mRNA
Deferoxamine results in decreased expression of DNMT1 mRNA		 CTD PMID:23483119 NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,342...10,231,286 		JBrowse link
G DNMT3A DNA methyltransferase 3 alpha decreases expression
increases expression		 EXP Deferoxamine results in decreased expression of DNMT3A mRNA
Deferoxamine results in increased expression of DNMT3A mRNA		 CTD PMID:23483119 NCBI chr 2:25,227,874...25,342,590
Ensembl chr 2:25,227,855...25,342,590 		JBrowse link
G DNMT3B DNA methyltransferase 3 beta decreases expression
increases expression		 EXP Deferoxamine results in decreased expression of DNMT3B mRNA
Deferoxamine results in increased expression of DNMT3B mRNA		 CTD PMID:23483119 NCBI chr20:32,762,385...32,809,356
Ensembl chr20:32,762,385...32,809,359 		JBrowse link
G DUOX1 dual oxidase 1 multiple interactions EXP Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of DUOX1 mRNA] CTD PMID:21703343 NCBI chr15:45,129,994...45,165,574
Ensembl chr15:45,129,933...45,165,576 		JBrowse link
G DUOX2 dual oxidase 2 multiple interactions EXP Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of DUOX2 mRNA] CTD PMID:21703343 NCBI chr15:45,092,650...45,114,172
Ensembl chr15:45,092,650...45,114,172 		JBrowse link
G DUSP1 dual specificity phosphatase 1 increases expression ISO Deferoxamine results in increased expression of DUSP1 mRNA CTD PMID:11577072 NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195 		JBrowse link
G EDN1 endothelin 1 increases expression ISO Deferoxamine results in increased expression of EDN1 protein CTD PMID:9357851 NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194 		JBrowse link
G EGFR epidermal growth factor receptor multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA; Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA] CTD PMID:15626777 PMID:35690295 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628 		JBrowse link
G EGLN1 egl-9 family hypoxia inducible factor 1 decreases expression EXP Deferoxamine results in decreased expression of EGLN1 protein CTD PMID:22245592 NCBI chr 1:231,363,756...231,422,287
Ensembl chr 1:231,363,751...231,422,287 		JBrowse link
G EHMT2 euchromatic histone lysine methyltransferase 2 decreases expression EXP Deferoxamine results in decreased expression of EHMT2 mRNA CTD PMID:23483119 NCBI chr 6:31,879,759...31,897,698
Ensembl chr 6:31,879,759...31,897,698 		JBrowse link
G ELANE elastase, neutrophil expressed multiple interactions EXP Deferoxamine inhibits the reaction [ELANE protein results in increased expression of MUC5AC mRNA] CTD PMID:11919081 NCBI chr19:852,303...856,243
Ensembl chr19:851,014...856,247 		JBrowse link
G ENO1 enolase 1 increases expression EXP Deferoxamine results in increased expression of ENO1 mRNA CTD PMID:16227210 NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190 		JBrowse link
G EPAS1 endothelial PAS domain protein 1 multiple interactions
increases expression
increases stability		 EXP
ISO		 Deferoxamine inhibits the reaction [EPAS1 protein results in increased degradation of COX4I1 protein]
Deferoxamine results in increased expression of EPAS1 protein
Deferoxamine results in increased stability of EPAS1 protein		 CTD PMID:18353899 PMID:18515279 PMID:21558026 PMID:22447124 PMID:26735578 More... NCBI chr 2:46,297,407...46,386,697
Ensembl chr 2:46,293,667...46,386,697 		JBrowse link
G EPO erythropoietin increases expression
increases stability
multiple interactions		 EXP
ISO		 Deferoxamine results in increased expression of EPO mRNA
Deferoxamine deficiency results in increased expression of EPO mRNA; Deferoxamine results in increased expression of EPO mRNA
Deferoxamine deficiency results in increased stability of EPO mRNA
Deferoxamine results in increased expression of EPO mRNA; Deferoxamine results in increased expression of EPO protein
Deferoxamine inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein]		 CTD PMID:9927288 PMID:10559391 PMID:10699462 PMID:10756076 PMID:21558026 NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700 		JBrowse link
G ERN1 endoplasmic reticulum to nucleus signaling 1 multiple interactions EXP Deferoxamine promotes the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] CTD PMID:32283200 NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819 		JBrowse link
G ERO1A endoplasmic reticulum oxidoreductase 1 alpha increases expression EXP
ISO		 Deferoxamine results in increased expression of ERO1A mRNA CTD PMID:12752442 NCBI chr14:52,639,915...52,695,558
Ensembl chr14:52,639,915...52,695,900 		JBrowse link
G ERP29 endoplasmic reticulum protein 29 decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of ERP29 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ERP29 protein]		 CTD PMID:19515424 NCBI chr12:112,013,426...112,023,449
Ensembl chr12:112,013,348...112,023,449 		JBrowse link
G EXO1 exonuclease 1 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA] CTD PMID:35690295 NCBI chr 1:241,847,986...241,889,939
Ensembl chr 1:241,847,967...241,895,148 		JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions EXP Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased expression of F3 mRNA] CTD PMID:25858758 NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759 		JBrowse link
G FABP4 fatty acid binding protein 4 decreases expression EXP Deferoxamine results in decreased expression of FABP4 mRNA CTD PMID:12032628 NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236 		JBrowse link
G FASN fatty acid synthase multiple interactions EXP [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of FASN protein]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of FASN protein] CTD PMID:34648812 NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294 		JBrowse link
G FECH ferrochelatase multiple interactions
decreases expression		 EXP ferric chloride inhibits the reaction [Deferoxamine results in decreased expression of FECH protein] CTD PMID:30517741 NCBI chr18:57,544,377...57,586,702
Ensembl chr18:57,544,377...57,586,732 		JBrowse link
G FIS1 fission, mitochondrial 1 multiple interactions EXP [Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA] CTD PMID:33962019 NCBI chr 7:101,239,472...101,245,081
Ensembl chr 7:101,239,458...101,252,316 		JBrowse link
G FN1 fibronectin 1 multiple interactions EXP Deferoxamine inhibits the reaction [Artesunate results in decreased expression of FN1 mRNA] CTD PMID:30551460 NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073 		JBrowse link
G FTH1 ferritin heavy chain 1 decreases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in decreased expression of FTH1 protein
Deferoxamine inhibits the reaction [Benzene results in increased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [Iron-Dextran Complex results in increased expression of FTH1 protein]
Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in decreased expression of FTH1 protein]
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA		 CTD PMID:15893546 PMID:16568477 PMID:16777245 PMID:17469137 PMID:32687844 More... NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634 		JBrowse link
G FTL ferritin light chain multiple interactions
decreases expression		 EXP
ISO		 [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]
Deferoxamine inhibits the reaction [Benzene results in increased expression of FTL1 protein]
Deferoxamine results in decreased expression of FTL1 protein		 CTD PMID:12393473 PMID:12644586 PMID:15893546 PMID:16568477 PMID:35661779 NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,966,879 		JBrowse link
G FTMT ferritin mitochondrial multiple interactions EXP Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]] CTD PMID:12644586 NCBI chr 5:121,851,882...121,852,833
Ensembl chr 5:121,851,882...121,852,833 		JBrowse link
G GADD45A growth arrest and DNA damage inducible alpha increases expression EXP Deferoxamine results in increased expression of GADD45A mRNA CTD PMID:10397746 PMID:11468187 NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334 		JBrowse link
G GAPDH glyceraldehyde-3-phosphate dehydrogenase decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of GAPDH protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GAPDH protein]		 CTD PMID:19515424 NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374 		JBrowse link
G GAS1 growth arrest specific 1 multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of GAS1 mRNA CTD PMID:12393473 NCBI chr 9:86,944,362...86,947,506
Ensembl chr 9:86,944,362...86,947,506 		JBrowse link
G GBE1 1,4-alpha-glucan branching enzyme 1 increases expression EXP
ISO		 Deferoxamine results in increased expression of GBE1 mRNA CTD PMID:15094311 NCBI chr 3:81,489,703...81,761,645
Ensembl chr 3:81,489,703...81,761,645 		JBrowse link
G GCK glucokinase affects expression ISO Deferoxamine affects the expression of GCK mRNA CTD PMID:9761743 NCBI chr 7:44,143,213...44,189,439
Ensembl chr 7:44,143,213...44,198,170 		JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit multiple interactions ISO Deferoxamine inhibits the reaction [Benzene results in decreased expression of GCLC mRNA] CTD PMID:35661779 NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970 		JBrowse link
G GLO1 glyoxalase I increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of GLO1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GLO1 protein]		 CTD PMID:19515424 NCBI chr 6:38,675,925...38,703,145
Ensembl chr 6:38,675,925...38,703,145 		JBrowse link
G GOSR1 golgi SNAP receptor complex member 1 multiple interactions EXP GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]] CTD PMID:31066958 NCBI chr17:30,477,408...30,527,592
Ensembl chr17:30,477,362...30,527,592 		JBrowse link
G GPX4 glutathione peroxidase 4 multiple interactions ISO
EXP		 Deferoxamine inhibits the reaction [Benzene results in decreased expression of GPX4 mRNA]; Deferoxamine inhibits the reaction [Benzene results in decreased expression of GPX4 protein]; Deferoxamine inhibits the reaction [Busulfan results in decreased expression of GPX4 protein]
Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]		 CTD PMID:32416107 PMID:35661779 PMID:36843388 NCBI chr19:1,103,994...1,106,779
Ensembl chr19:1,103,982...1,106,791 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta multiple interactions
decreases phosphorylation		 EXP
ISO		 Deferoxamine inhibits the reaction [Fenretinide results in increased phosphorylation of GSK3B protein]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased phosphorylation of GSK3B protein]
Deferoxamine results in decreased phosphorylation of GSK3B protein		 CTD PMID:25246272 PMID:34577062 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G GSR glutathione-disulfide reductase multiple interactions ISO Deferoxamine inhibits the reaction [Potassium Dichromate results in decreased activity of GSR protein] CTD PMID:22115772 NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846 		JBrowse link
G HAMP hepcidin antimicrobial peptide multiple interactions
decreases expression
affects expression		 EXP
ISO		 Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Deferoxamine promotes the reaction [ferric ammonium citrate results in decreased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]
Deferoxamine results in decreased expression of HAMP protein
Deferoxamine affects the expression of HAMP mRNA		 CTD PMID:21558026 PMID:25633564 NCBI chr19:35,282,528...35,285,143
Ensembl chr19:35,280,716...35,285,143 		JBrowse link
G HAVCR1 hepatitis A virus cellular receptor 1 multiple interactions ISO Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of HAVCR1 protein] CTD PMID:30431687 NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396 		JBrowse link
G HIF1A hypoxia inducible factor 1 subunit alpha multiple interactions
increases expression
increases stability
increases activity
decreases degradation
affects localization		 EXP
ISO		 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Doxorubicin co-treated with Deferoxamine] results in increased expression of HIF1A protein; [Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA; [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Arsenic Trioxide promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; Cadmium inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HIF1A mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HIF1A protein]]; Deferoxamine promotes the reaction [[HIF1A protein binds to VEGFA promoter] which results in increased expression of VEGFA mRNA]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Deferoxamine results in increased expression of and results in increased stability of HIF1A protein; Deferoxamine results in increased stability of and results in increased expression of HIF1A protein; dihydrotanshinone I inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ST6GAL1 protein promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]
Deferoxamine results in increased expression of HIF1A mRNA; Deferoxamine results in increased expression of HIF1A protein
Deferoxamine results in increased stability of HIF1A protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]
Deferoxamine results in increased activity of HIF1A protein
[Deferoxamine results in increased activity of HIF1A protein] which results in decreased susceptibility to Carmustine
Deferoxamine results in decreased degradation of HIF1A protein
Deferoxamine affects the localization of HIF1A protein		 CTD PMID:10559391 PMID:10866824 PMID:11286986 PMID:12393473 PMID:14604972 More... NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259 		JBrowse link
G HIF3A hypoxia inducible factor 3 subunit alpha increases expression EXP Deferoxamine results in increased expression of HIF3A protein CTD PMID:16775626 NCBI chr19:46,297,042...46,343,433
Ensembl chr19:46,297,042...46,343,433 		JBrowse link
G HK2 hexokinase 2 increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of HK2 protein
Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HK2 mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HK2 protein]]; Doxorubicin inhibits the reaction [Deferoxamine results in increased expression of HK2 protein]		 CTD PMID:34126102 PMID:36116563 NCBI chr 2:74,834,127...74,893,359
Ensembl chr 2:74,834,127...74,893,359 		JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions
decreases degradation
decreases expression		 ISO
EXP		 Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]
Deferoxamine results in decreased degradation of HMOX1 protein
Deferoxamine results in decreased expression of HMOX1 mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; Deferoxamine affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Fenretinide results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Zinc results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Zinc results in increased expression of HMOX1 protein]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]]
Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; Deferoxamine inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]		 CTD PMID:9747510 PMID:10814519 PMID:12393473 PMID:16439612 PMID:18073186 More... NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214 		JBrowse link
G HSPA1A heat shock protein family A (Hsp70) member 1A multiple interactions
decreases expression		 EXP ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPA1A protein]
Deferoxamine results in decreased expression of HSPA1A protein		 CTD PMID:19515424 NCBI chr 6:31,815,543...31,817,942
Ensembl chr 6:31,815,543...31,817,946 		JBrowse link
G HSPA1L heat shock protein family A (Hsp70) member 1 like multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA1L mRNA CTD PMID:12393473 NCBI chr 6:31,809,619...31,815,283
Ensembl chr 6:31,809,619...31,815,283 		JBrowse link
G HSPA6 heat shock protein family A (Hsp70) member 6 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA] CTD PMID:35690295 NCBI chr 1:161,524,540...161,526,894
Ensembl chr 1:161,524,540...161,526,894 		JBrowse link
G HSPA9 heat shock protein family A (Hsp70) member 9 multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA9 mRNA CTD PMID:12393473 NCBI chr 5:138,553,756...138,575,401
Ensembl chr 5:138,553,756...138,575,675 		JBrowse link
G HSPD1 heat shock protein family D (Hsp60) member 1 multiple interactions
decreases expression		 EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA; ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPD1 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA]
Deferoxamine results in decreased expression of HSPD1 protein		 CTD PMID:19515424 PMID:24170104 PMID:35690295 NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737 		JBrowse link
G HSPH1 heat shock protein family H (Hsp110) member 1 multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPH1 mRNA CTD PMID:12393473 NCBI chr13:31,134,973...31,162,388
Ensembl chr13:31,134,973...31,162,388 		JBrowse link
G ICAM1 intercellular adhesion molecule 1 multiple interactions EXP [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] CTD PMID:12633744 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615 		JBrowse link
G IL10 interleukin 10 multiple interactions ISO Deferoxamine inhibits the reaction [Copper Sulfate results in decreased secretion of IL10 protein] CTD PMID:30431687 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541 		JBrowse link
G IL1A interleukin 1 alpha multiple interactions EXP Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of IL1A mRNA] CTD PMID:21703343 NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493 		JBrowse link
G IL1B interleukin 1 beta multiple interactions
increases expression
decreases expression		 EXP
ISO		 Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; ferric chloride inhibits the reaction [Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]
Deferoxamine results in increased expression of IL1B mRNA
Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL1B protein]
Deferoxamine results in decreased expression of IL1B mRNA		 CTD PMID:9851740 PMID:18403674 PMID:20801209 PMID:32816093 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL4 interleukin 4 multiple interactions ISO Deferoxamine inhibits the reaction [Mercuric Chloride results in increased expression of IL4 mRNA] CTD PMID:11222498 NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678 		JBrowse link
G IL6 interleukin 6 multiple interactions EXP
ISO		 Deferoxamine inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of and results in increased secretion of IL6 protein]; Deferoxamine inhibits the reaction [Coal Ash results in increased expression of IL6 protein]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of IL6 protein]; Deferoxamine inhibits the reaction [Asbestos, Amphibole results in increased expression of IL6 mRNA]		 CTD PMID:9344885 PMID:22168577 PMID:24296301 PMID:34577062 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002 		JBrowse link
G INS-IGF2 INS-IGF2 readthrough increases secretion ISO Deferoxamine results in increased secretion of INS1 protein CTD PMID:30382123 NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209 		JBrowse link
G IREB2 iron responsive element binding protein 2 increases expression
increases activity
multiple interactions		 ISO
EXP		 Deferoxamine results in increased expression of IREB2 protein
Deferoxamine results in increased activity of IREB2 protein
Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein]; Deferoxamine results in increased expression of and results in increased activity of IREB2 protein		 CTD PMID:10397746 PMID:11054110 PMID:16135072 PMID:16568477 PMID:17469137 More... NCBI chr15:78,437,431...78,501,453
Ensembl chr15:78,437,431...78,501,453 		JBrowse link
G ITGB3 integrin subunit beta 3 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of ITGB3 mRNA
Deferoxamine inhibits the reaction [TF protein results in increased expression of ITGB3 mRNA]		 CTD PMID:31238089 NCBI chr17:47,253,827...47,313,743
Ensembl chr17:47,253,827...47,313,743 		JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in increased expression of JUN mRNA CTD PMID:12393473 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048 		JBrowse link
G KDM1A lysine demethylase 1A multiple interactions EXP Deferoxamine results in decreased expression of and results in decreased activity of KDM1A protein CTD PMID:23483119 NCBI chr 1:23,019,468...23,083,689
Ensembl chr 1:23,019,443...23,083,689 		JBrowse link
G KDM3A lysine demethylase 3A increases expression EXP Deferoxamine results in increased expression of KDM3A protein CTD PMID:23546878 NCBI chr 2:86,437,044...86,492,716
Ensembl chr 2:86,440,647...86,492,716 		JBrowse link
G KDM4A lysine demethylase 4A multiple interactions EXP Deferoxamine results in decreased expression of and results in decreased activity of KDM4A protein CTD PMID:23483119 NCBI chr 1:43,650,149...43,705,518
Ensembl chr 1:43,650,149...43,705,518 		JBrowse link
G KDR kinase insert domain receptor multiple interactions EXP [Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA] CTD PMID:33962019 NCBI chr 4:55,078,481...55,125,595
Ensembl chr 4:55,078,481...55,125,595 		JBrowse link
G LCN2 lipocalin 2 multiple interactions
increases expression		 ISO Deferoxamine affects the reaction [Magnetite Nanoparticles results in increased expression of LCN2 mRNA]; Deferoxamine inhibits the reaction [LCN2 protein results in decreased secretion of VEGFA protein]
Deferoxamine results in increased expression of LCN2 mRNA		 CTD PMID:17114340 PMID:23086747 NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453 		JBrowse link
G LDHA lactate dehydrogenase A increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of LDHA mRNA
Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of LDHA mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of LDHA protein]]		 CTD PMID:34998824 PMID:36116563 NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425 		JBrowse link
G LEP leptin increases expression
increases secretion		 EXP
ISO		 Deferoxamine results in increased expression of LEP mRNA
Deferoxamine results in increased secretion of LEP protein		 CTD PMID:12032628 NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629 		JBrowse link
G LIPE lipase E, hormone sensitive type decreases expression EXP Deferoxamine results in decreased expression of LIPE mRNA CTD PMID:12032628 NCBI chr19:42,401,514...42,427,388
Ensembl chr19:42,401,514...42,427,388 		JBrowse link
G LOX lysyl oxidase multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in increased expression of LOX mRNA CTD PMID:12393473 NCBI chr 5:122,063,195...122,078,259
Ensembl chr 5:122,063,195...122,078,413 		JBrowse link
G MAP1LC3A microtubule associated protein 1 light chain 3 alpha multiple interactions EXP Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of MAP1LC3A protein] CTD PMID:21742779 NCBI chr20:34,546,844...34,560,345
Ensembl chr20:34,546,854...34,560,345 		JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of MAP1LC3B protein
Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]		 CTD PMID:25301941 PMID:32687844 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779 		JBrowse link
G MAP3K5 mitogen-activated protein kinase kinase kinase 5 multiple interactions EXP Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAP3K5 protein] CTD PMID:20206247 NCBI chr 6:136,557,046...136,793,091
Ensembl chr 6:136,557,046...136,793,097 		JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation		 ISO
EXP		 Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; Deferoxamine promotes the reaction [Manganese results in increased phosphorylation of MAPK1 protein]
Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]
[Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK1 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]
Deferoxamine results in increased phosphorylation of MAPK1 protein		 CTD PMID:11933051 PMID:16527254 PMID:18032466 PMID:20368581 PMID:31066958 More... NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO
EXP		 Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein]; Deferoxamine promotes the reaction [Manganese results in increased phosphorylation of MAPK3 protein]
Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]]
[Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK3 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]
Deferoxamine results in increased phosphorylation of MAPK3 protein		 CTD PMID:11933051 PMID:16527254 PMID:18032466 PMID:20368581 PMID:31066958 More... NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MAPK8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions		 EXP Deferoxamine results in increased phosphorylation of MAPK8 protein
Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK8 protein]		 CTD PMID:20206247 PMID:20368581 NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360 		JBrowse link
G MAPK9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions		 EXP Deferoxamine results in increased phosphorylation of MAPK9 protein
Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK9 protein]		 CTD PMID:20206247 PMID:20368581 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099 		JBrowse link
G MCL1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases cleavage		 EXP Nitroprusside inhibits the reaction [Deferoxamine results in increased cleavage of MCL1 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased cleavage of MCL1 protein] CTD PMID:16374551 NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,560,895...150,579,738 		JBrowse link
G MFF mitochondrial fission factor increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of MFF mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA]		 CTD PMID:33962019 NCBI chr 2:227,325,251...227,357,836
Ensembl chr 2:227,325,151...227,357,833 		JBrowse link
G MFN2 mitofusin 2 multiple interactions EXP [Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA; Melatonin affects the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA] CTD PMID:33962019 NCBI chr 1:11,980,444...12,013,508
Ensembl chr 1:11,980,181...12,015,211 		JBrowse link
G MIEF2 mitochondrial elongation factor 2 multiple interactions
increases expression		 EXP [Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA]
Deferoxamine results in increased expression of MIEF2 mRNA		 CTD PMID:33962019 NCBI chr17:18,260,662...18,266,552
Ensembl chr17:18,260,597...18,266,552 		JBrowse link
G MIR155 microRNA 155 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA] CTD PMID:35690295 NCBI chr21:25,573,980...25,574,044
Ensembl chr21:25,573,980...25,574,044 		JBrowse link
G MIR184 microRNA 184 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR184 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA] CTD PMID:35690295 NCBI chr15:79,209,788...79,209,871
Ensembl chr15:79,209,788...79,209,871 		JBrowse link
G MIR210 microRNA 210 increases expression
increases expression 		ISO
EXP		 Deferoxamine results in increased expression of MIR210 mRNA
desferrioxamine B increases expression of MIR210 miRNA in trophoblast cells 		CTD
RGD		 PMID:24577088 PMID:22840297 RGD:155631283 NCBI chr11:568,089...568,198
Ensembl chr11:568,089...568,198 		JBrowse link
G MLH1 mutL homolog 1 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA] CTD PMID:35690295 NCBI chr 3:36,993,466...37,050,846
Ensembl chr 3:36,993,226...37,050,896 		JBrowse link
G MMP1 matrix metallopeptidase 1 multiple interactions EXP [Deferoxamine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [[Amitrole co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA] CTD PMID:10464329 PMID:19136476 NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160 		JBrowse link
G MMP2 matrix metallopeptidase 2 multiple interactions
decreases activity		 EXP Calcium Chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]; Deferoxamine inhibits the reaction [ferumoxides results in increased activity of MMP2 protein]; ferric chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein] CTD PMID:10086886 PMID:20338187 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691 		JBrowse link
G MMP3 matrix metallopeptidase 3 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA] CTD PMID:35690295 NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609 		JBrowse link
G MMP9 matrix metallopeptidase 9 decreases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in decreased expression of MMP9 mRNA
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]
Deferoxamine inhibits the reaction [TF protein results in increased expression of MMP9 mRNA]; TF protein affects the reaction [Deferoxamine results in increased expression of MMP9 mRNA]		 CTD PMID:31238089 PMID:35690295 NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561 		JBrowse link
G MRPS9 mitochondrial ribosomal protein S9 multiple interactions
increases expression		 EXP ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of MRPS9 protein] CTD PMID:19515424 NCBI chr 2:105,038,069...105,099,960
Ensembl chr 2:105,038,069...105,099,960 		JBrowse link
G MSR1 macrophage scavenger receptor 1 multiple interactions EXP Deferoxamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA] CTD PMID:9614211 NCBI chr 8:16,107,881...16,192,651
Ensembl chr 8:16,107,878...16,567,490 		JBrowse link
G MT-ATP6 mitochondrially encoded ATP synthase membrane subunit 6 decreases expression ISO Deferoxamine results in decreased expression of ATP6 mRNA CTD PMID:31238089 NCBI chr MT:8,527...9,207
Ensembl chr MT:8,527...9,207 		JBrowse link
G MT-ATP8 mitochondrially encoded ATP synthase membrane subunit 8 decreases expression ISO Deferoxamine results in decreased expression of ATP8 mRNA CTD PMID:31238089 NCBI chr MT:8,366...8,572
Ensembl chr MT:8,366...8,572 		JBrowse link
G MT-CO1 mitochondrially encoded cytochrome c oxidase I decreases expression ISO Deferoxamine results in decreased expression of COX1 mRNA CTD PMID:31238089 NCBI chr MT:5,904...7,445
Ensembl chr MT:5,904...7,445 		JBrowse link
G MT-CO2 mitochondrially encoded cytochrome c oxidase II decreases expression ISO Deferoxamine results in decreased expression of COX2 mRNA CTD PMID:31238089 NCBI chr MT:7,586...8,269
Ensembl chr MT:7,586...8,269 		JBrowse link
G MT-CO3 mitochondrially encoded cytochrome c oxidase III decreases expression ISO Deferoxamine results in decreased expression of COX3 mRNA CTD PMID:31238089 NCBI chr MT:9,207...9,990
Ensembl chr MT:9,207...9,990 		JBrowse link
G MT-CYB mitochondrially encoded cytochrome b decreases expression ISO Deferoxamine results in decreased expression of CYTB mRNA CTD PMID:31238089 NCBI chr MT:14,747...15,887
Ensembl chr MT:14,747...15,887 		JBrowse link
G MT-ND1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 decreases expression ISO Deferoxamine results in decreased expression of ND1 mRNA CTD PMID:31238089 NCBI chr MT:3,307...4,262
Ensembl chr MT:3,307...4,262 		JBrowse link
G MT-ND2 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 decreases expression ISO Deferoxamine results in decreased expression of ND2 mRNA CTD PMID:31238089 NCBI chr MT:4,470...5,511
Ensembl chr MT:4,470...5,511 		JBrowse link
G MT-ND3 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 decreases expression ISO Deferoxamine results in decreased expression of ND3 mRNA CTD PMID:31238089 NCBI chr MT:10,059...10,404
Ensembl chr MT:10,059...10,404 		JBrowse link
G MT-ND4 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 decreases expression ISO Deferoxamine results in decreased expression of ND4 mRNA CTD PMID:31238089 NCBI chr MT:10,760...12,137
Ensembl chr MT:10,760...12,137 		JBrowse link
G MT-ND4L mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L decreases expression ISO Deferoxamine results in decreased expression of ND4L mRNA CTD PMID:31238089 NCBI chr MT:10,470...10,766
Ensembl chr MT:10,470...10,766 		JBrowse link
G MT-ND5 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 decreases expression ISO Deferoxamine results in decreased expression of ND5 mRNA CTD PMID:31238089 NCBI chr MT:12,337...14,148
Ensembl chr MT:12,337...14,148 		JBrowse link
G MT-ND6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 decreases expression ISO Deferoxamine results in decreased expression of ND6 mRNA CTD PMID:31238089 NCBI chr MT:14,149...14,673
Ensembl chr MT:14,149...14,673 		JBrowse link
G MT2A metallothionein 2A multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in increased expression of MT2A mRNA CTD PMID:12393473 NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497 		JBrowse link
G MTOR mechanistic target of rapamycin kinase multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA] CTD PMID:35690295 NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556 		JBrowse link
G MUC5AC mucin 5AC, oligomeric mucus/gel-forming multiple interactions EXP Deferoxamine inhibits the reaction [ELANE protein results in increased expression of MUC5AC mRNA] CTD PMID:11919081 NCBI chr11:1,157,953...1,201,138
Ensembl chr11:1,157,953...1,201,138 		JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor increases degradation
decreases expression
multiple interactions		 EXP Deferoxamine results in increased degradation of MYC protein
Deferoxamine results in decreased expression of MYC protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA		 CTD PMID:12393473 PMID:20046830 PMID:22245592 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951 		JBrowse link
G NCOA4 nuclear receptor coactivator 4 multiple interactions EXP Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of NCOA4 protein]; Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of NCOA4 protein] CTD PMID:32283200 PMID:32687844 PMID:36843388 NCBI chr10:46,005,088...46,030,623
Ensembl chr10:46,005,088...46,030,623 		JBrowse link
G NDRG1 N-myc downstream regulated 1 increases expression
decreases response to substance		 EXP Deferoxamine results in increased expression of NDRG1 mRNA; Deferoxamine results in increased expression of NDRG1 protein
NDRG1 protein results in decreased susceptibility to Deferoxamine		 CTD PMID:11006124 PMID:24532803 NCBI chr 8:133,237,175...133,297,252
Ensembl chr 8:133,237,175...133,302,022 		JBrowse link
G NDUFB8 NADH:ubiquinone oxidoreductase subunit B8 decreases expression ISO Deferoxamine results in decreased expression of NDUFB8 protein CTD PMID:31238089 NCBI chr10:100,523,729...100,529,923
Ensembl chr10:100,523,740...100,530,000 		JBrowse link
G NES nestin decreases expression ISO Deferoxamine results in decreased expression of NES mRNA CTD PMID:16772336 NCBI chr 1:156,668,763...156,677,407
Ensembl chr 1:156,668,763...156,677,407 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 multiple interactions EXP
ISO		 Deferoxamine inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of NFE2L2 protein]; Deferoxamine inhibits the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]]
Deferoxamine inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein]		 CTD PMID:26945724 PMID:31066958 PMID:32416107 PMID:36450496 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
G NFKBIA NFKB inhibitor alpha multiple interactions ISO Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of NFKBIA mRNA] CTD PMID:30431687 NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749 		JBrowse link
G NOS2 nitric oxide synthase 2 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of NOS2 mRNA
Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Deferoxamine]
[Deferoxamine results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide		 CTD PMID:7532384 PMID:18073202 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of NQO1 mRNA
Deferoxamine inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]		 CTD PMID:14645679 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G OLR1 oxidized low density lipoprotein receptor 1 decreases expression EXP Deferoxamine results in decreased expression of OLR1 protein CTD PMID:24170104 NCBI chr12:10,158,301...10,176,266
Ensembl chr12:10,158,301...10,172,138 		JBrowse link
G OPA1 OPA1 mitochondrial dynamin like GTPase increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of OPA1 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA]		 CTD PMID:33962019 NCBI chr 3:193,593,208...193,697,811
Ensembl chr 3:193,593,144...193,697,811 		JBrowse link
G P4HA1 prolyl 4-hydroxylase subunit alpha 1 decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of P4HA1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of P4HA1 protein]		 CTD PMID:19515424 NCBI chr10:73,007,217...73,096,866
Ensembl chr10:73,007,217...73,096,974 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases cleavage
multiple interactions		 EXP Deferoxamine results in increased cleavage of PARP1 protein
Indomethacin promotes the reaction [Deferoxamine results in increased cleavage of PARP1 protein]; Sulindac promotes the reaction [Deferoxamine results in increased cleavage of PARP1 protein]		 CTD PMID:21882223 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PDGFA platelet derived growth factor subunit A multiple interactions ISO Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of PDGFA mRNA] CTD PMID:11306436 NCBI chr 7:497,258...520,700
Ensembl chr 7:497,258...520,296 		JBrowse link
G PDGFB platelet derived growth factor subunit B multiple interactions ISO Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of AKT1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein] CTD PMID:18032466 NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982 		JBrowse link
G PDGFRB platelet derived growth factor receptor beta decreases expression ISO Deferoxamine results in decreased expression of PDGFRB protein CTD PMID:18032466 NCBI chr 5:150,113,839...150,155,845
Ensembl chr 5:150,113,839...150,155,872 		JBrowse link
G PDHB pyruvate dehydrogenase E1 subunit beta increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of PDHB protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PDHB protein]		 CTD PMID:19515424 NCBI chr 3:58,427,630...58,433,832
Ensembl chr 3:58,427,630...58,433,857 		JBrowse link
G PDK1 pyruvate dehydrogenase kinase 1 increases expression EXP Deferoxamine results in increased expression of PDK1 mRNA CTD PMID:21558026 NCBI chr 2:172,555,373...172,724,312
Ensembl chr 2:172,555,373...172,608,669 		JBrowse link
G PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA CTD PMID:16025159 NCBI chr 3:48,517,684...48,563,136
Ensembl chr 3:48,517,684...48,562,015 		JBrowse link
G PGK1 phosphoglycerate kinase 1 multiple interactions
increases expression
decreases expression		 EXP ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PGK1 protein]
Deferoxamine results in increased expression of PGK1 mRNA
Deferoxamine results in decreased expression of PGK1 protein		 CTD PMID:19515424 PMID:22447124 PMID:34998824 NCBI chr  X:78,104,248...78,129,295
Ensembl chr  X:77,910,739...78,129,295 		JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA] CTD PMID:35690295 NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,740...68,301,821 		JBrowse link
G PINK1 PTEN induced kinase 1 multiple interactions EXP [Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA] CTD PMID:33962019 NCBI chr 1:20,633,458...20,651,511
Ensembl chr 1:20,633,458...20,651,511 		JBrowse link
G PLAGL2 PLAG1 like zinc finger 2 multiple interactions ISO Deferoxamine results in increased expression of and affects the localization of PLAGL2 protein CTD PMID:11832486 NCBI chr20:32,192,504...32,207,743
Ensembl chr20:32,192,504...32,207,743 		JBrowse link
G PLAU plasminogen activator, urokinase multiple interactions EXP Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA] CTD PMID:17571974 NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496 		JBrowse link
G PLIN2 perilipin 2 multiple interactions EXP [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of PLIN2 protein]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of PLIN2 protein] CTD PMID:34648812 NCBI chr 9:19,108,388...19,127,492
Ensembl chr 9:19,108,375...19,149,290 		JBrowse link
G PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions
increases expression		 EXP [Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA]
Deferoxamine results in increased expression of PMAIP1 mRNA		 CTD PMID:33962019 NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305 		JBrowse link
G PMP22 peripheral myelin protein 22 multiple interactions EXP [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of PMP22 mRNA CTD PMID:12393473 NCBI chr17:15,229,779...15,265,326
Ensembl chr17:15,229,773...15,272,292 		JBrowse link
G POU5F1 POU class 5 homeobox 1 increases expression EXP Deferoxamine results in increased expression of POU5F1 mRNA CTD PMID:22447124 NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731 		JBrowse link
G PPIA peptidylprolyl isomerase A multiple interactions
decreases expression		 EXP ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PPIA protein]
Deferoxamine results in decreased expression of PPIA protein		 CTD PMID:19515424 NCBI chr 7:44,796,681...44,803,117
Ensembl chr 7:44,796,680...44,824,564 		JBrowse link
G PRKCD protein kinase C delta increases phosphorylation EXP Deferoxamine results in increased phosphorylation of PRKCD protein CTD PMID:17097691 NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717 		JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
increases stability		 EXP
ISO		 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; [Sulindac co-treated with Deferoxamine] results in increased expression of PTGS2 protein; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; Indomethacin promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]
Deferoxamine results in increased expression of PTGS2 mRNA; Deferoxamine results in increased expression of PTGS2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; Deferoxamine inhibits the reaction [Benzene results in increased expression of PTGS2 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]
Deferoxamine results in increased stability of PTGS2 protein		 CTD PMID:16527254 PMID:21882223 PMID:32816093 PMID:35661779 PMID:36843388 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922 		JBrowse link
G RACK1 receptor for activated C kinase 1 decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of RACK1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of RACK1 protein]		 CTD PMID:19515424 NCBI chr 5:181,236,897...181,243,906
Ensembl chr 5:181,236,897...181,248,096 		JBrowse link
G RAMP2 receptor activity modifying protein 2 decreases expression EXP Deferoxamine results in decreased expression of RAMP2 mRNA CTD PMID:11754965 NCBI chr17:42,761,227...42,763,041
Ensembl chr17:42,758,447...42,763,041 		JBrowse link
G RB1 RB transcriptional corepressor 1 decreases phosphorylation EXP Deferoxamine results in decreased phosphorylation of RB1 protein CTD PMID:11468187 NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436 		JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions ISO Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of RELA protein] CTD PMID:34577062 NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090 		JBrowse link
G RUNX2 RUNX family transcription factor 2 decreases expression ISO Deferoxamine results in decreased expression of RUNX2 mRNA CTD PMID:16772336 NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349 		JBrowse link
G SAG S-antigen visual arrestin multiple interactions ISO Deferoxamine inhibits the reaction [SAG results in increased abundance of Free Radicals] CTD PMID:8407215 NCBI chr 2:233,307,816...233,347,055
Ensembl chr 2:233,307,816...233,347,055 		JBrowse link
G SDHB succinate dehydrogenase complex iron sulfur subunit B decreases expression ISO Deferoxamine results in decreased expression of SDHB protein CTD PMID:31238089 NCBI chr 1:17,018,722...17,054,032
Ensembl chr 1:17,018,664...17,054,032 		JBrowse link
G SELE selectin E multiple interactions EXP [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein] CTD PMID:12633744 NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705 		JBrowse link
G SESN2 sestrin 2 multiple interactions EXP Deferoxamine inhibits the reaction [erastin results in increased expression of SESN2 protein] CTD PMID:31323261 NCBI chr 1:28,259,518...28,282,491
Ensembl chr 1:28,259,518...28,282,491 		JBrowse link
G SETD1A SET domain containing 1A, histone lysine methyltransferase increases expression EXP Deferoxamine results in increased expression of SETD1A mRNA CTD PMID:23483119 NCBI chr16:30,957,754...30,984,664
Ensembl chr16:30,957,294...30,984,664 		JBrowse link
G SETD2 SET domain containing 2, histone lysine methyltransferase increases expression
affects expression		 EXP Deferoxamine results in increased expression of SETD2 mRNA
Deferoxamine affects the expression of SETD2 mRNA		 CTD PMID:23483119 NCBI chr 3:47,016,436...47,164,840
Ensembl chr 3:47,016,428...47,164,113 		JBrowse link
G SIRT1 sirtuin 1 increases expression EXP Deferoxamine results in increased expression of SIRT1 protein CTD PMID:22245592 NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390 		JBrowse link
G SLC11A2 solute carrier family 11 member 2 multiple interactions
decreases expression
increases expression		 ISO
EXP		 [Deferoxamine co-treated with Manganese] results in increased expression of SLC11A2; [Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 protein]] which results in increased uptake of Copper; Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 mRNA]; Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 protein]
Deferoxamine results in decreased expression of SLC11A2 mRNA
Deferoxamine results in increased expression of SLC11A2 protein
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [Deferoxamine results in increased expression of SLC11A2 protein] which results in increased uptake of Manganese; Deferoxamine promotes the reaction [Deferoxamine results in increased expression of SLC11A2 protein]		 CTD PMID:11933051 PMID:12393473 PMID:23764342 PMID:24089420 NCBI chr12:50,952,263...51,028,886
Ensembl chr12:50,979,401...51,028,566 		JBrowse link
G SLC19A2 solute carrier family 19 member 2 decreases expression EXP Deferoxamine results in decreased expression of SLC19A2 mRNA CTD PMID:34998824 NCBI chr 1:169,463,909...169,485,970
Ensembl chr 1:169,463,909...169,485,944 		JBrowse link
G SLC19A3 solute carrier family 19 member 3 decreases expression EXP Deferoxamine results in decreased expression of SLC19A3 mRNA CTD PMID:34998824 NCBI chr 2:227,683,763...227,718,028
Ensembl chr 2:227,683,763...227,718,028 		JBrowse link
G SLC2A1 solute carrier family 2 member 1 multiple interactions
increases expression		 EXP [Deferoxamine results in decreased abundance of Oxygen] which results in increased expression of SLC2A1 protein; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of SLC2A1 mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of SLC2A1 protein]]
Deferoxamine results in increased expression of SLC2A1 mRNA		 CTD PMID:12032628 PMID:17442736 PMID:21558026 PMID:36116563 NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893 		JBrowse link
G SLC2A4 solute carrier family 2 member 4 decreases expression EXP Deferoxamine results in decreased expression of SLC2A4 mRNA CTD PMID:12032628 NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257 		JBrowse link
G SLC40A1 solute carrier family 40 member 1 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of SLC40A1 protein
Deferoxamine inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein]		 CTD PMID:31238089 PMID:32416107 NCBI chr 2:189,560,590...189,580,786
Ensembl chr 2:189,560,590...189,583,758 		JBrowse link
G SLC44A4 solute carrier family 44 member 4 decreases expression EXP Deferoxamine results in decreased expression of SLC44A4 mRNA CTD PMID:34998824 NCBI chr 6:31,863,192...31,878,997
Ensembl chr 6:31,863,192...31,879,046 		JBrowse link
G SLC6A2 solute carrier family 6 member 2 decreases expression ISO Deferoxamine results in decreased expression of SLC6A2 protein CTD PMID:16650837 NCBI chr16:55,655,988...55,706,192
Ensembl chr16:55,655,988...55,707,645 		JBrowse link
G SLC7A11 solute carrier family 7 member 11 decreases expression
multiple interactions		 EXP
ISO		 Deferoxamine results in decreased expression of SLC7A11 mRNA
Deferoxamine affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of SLC7A11 protein]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]
Deferoxamine inhibits the reaction [Benzene results in decreased expression of SLC7A11 mRNA]; Deferoxamine promotes the reaction [Benzene results in decreased expression of SLC7A11 protein]		 CTD PMID:32816093 PMID:35661779 PMID:36450496 PMID:36843388 NCBI chr 4:138,164,097...138,312,671
Ensembl chr 4:138,164,097...138,242,349 		JBrowse link
G SLPI secretory leukocyte peptidase inhibitor decreases expression EXP Deferoxamine results in decreased expression of SLPI mRNA CTD PMID:32816093 NCBI chr20:45,252,239...45,254,564
Ensembl chr20:45,252,239...45,254,564 		JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA] CTD PMID:35690295 NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931 		JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions
increases expression		 EXP
ISO		 [Deferoxamine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD2 mRNA; Deferoxamine inhibits the reaction [[Amitrole co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; TRAP1 protein inhibits the reaction [Deferoxamine results in increased expression of SOD2 protein]
Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]		 CTD PMID:10464329 PMID:16927372 PMID:19063909 PMID:35690295 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529 		JBrowse link
G SP1 Sp1 transcription factor multiple interactions EXP [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein] CTD PMID:12633744 NCBI chr12:53,380,176...53,416,446
Ensembl chr12:53,380,176...53,416,446 		JBrowse link
G SP7 Sp7 transcription factor multiple interactions ISO Deferoxamine inhibits the reaction [Ascorbic Acid results in increased expression of SP7 mRNA] CTD PMID:21467157 NCBI chr12:53,326,575...53,344,793
Ensembl chr12:53,326,575...53,345,315 		JBrowse link
G SQSTM1 sequestosome 1 increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of SQSTM1 protein
[Copper co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; [Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]		 CTD PMID:25301941 PMID:32283200 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078 		JBrowse link
G SREBF1 sterol regulatory element binding transcription factor 1 multiple interactions EXP [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of SREBF1 protein] CTD PMID:34648812 NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002 		JBrowse link
G ST6GAL1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 multiple interactions EXP ST6GAL1 protein promotes the reaction [Deferoxamine results in increased expression of HIF1A protein] CTD PMID:29475939 NCBI chr 3:186,930,526...187,078,553
Ensembl chr 3:186,930,325...187,078,553 		JBrowse link
G STAT3 signal transducer and activator of transcription 3 multiple interactions ISO Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of STAT3 protein] CTD PMID:30431687 NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568 		JBrowse link
G SUV39H1 SUV39H1 histone lysine methyltransferase increases expression
decreases expression		 EXP Deferoxamine results in increased expression of SUV39H1 mRNA
Deferoxamine results in decreased expression of SUV39H1 mRNA		 CTD PMID:23483119 NCBI chr  X:48,695,554...48,709,016
Ensembl chr  X:48,695,554...48,709,016 		JBrowse link
G TET2 tet methylcytosine dioxygenase 2 decreases expression EXP Deferoxamine results in decreased expression of TET2 protein CTD PMID:23483119 NCBI chr 4:105,145,875...105,279,803
Ensembl chr 4:105,145,875...105,279,816 		JBrowse link
G TF transferrin multiple interactions ISO Deferoxamine affects the reaction [TF protein affects the expression of ATP6V0D2 mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; Deferoxamine inhibits the reaction [TF protein results in increased expression of CTSK mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased expression of ITGB3 mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased expression of MMP9 mRNA]; TF protein affects the reaction [Deferoxamine affects the expression of ATP6V0D2 mRNA]; TF protein affects the reaction [Deferoxamine results in decreased expression of CTSK mRNA]; TF protein affects the reaction [Deferoxamine results in increased expression of MMP9 mRNA]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein] CTD PMID:31238089 NCBI chr 3:133,661,998...133,796,641
Ensembl chr 3:133,746,040...133,796,641 		JBrowse link
G TFR2 transferrin receptor 2 decreases expression EXP Deferoxamine results in decreased expression of TFR2 protein CTD PMID:25633564 NCBI chr 7:100,620,420...100,641,552
Ensembl chr 7:100,620,416...100,642,779 		JBrowse link
G TFRC transferrin receptor increases expression
multiple interactions		 EXP
ISO		 Deferoxamine results in increased expression of TFRC mRNA; Deferoxamine results in increased expression of TFRC protein
Deferoxamine inhibits the reaction [Doxorubicin results in decreased expression of TFRC mRNA]
[Deferoxamine co-treated with Benzene] results in increased expression of TFRC protein; Deferoxamine affects the reaction [Magnetite Nanoparticles results in decreased expression of TFRC mRNA]; Deferoxamine promotes the reaction [Busulfan results in decreased expression of TFRC protein]
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Deferoxamine results in decreased abundance of Oxygen] which results in increased expression of TFRC protein		 CTD PMID:11054110 PMID:12393473 PMID:12807743 PMID:15993339 PMID:16039939 More... NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153 		JBrowse link
G TGFB1 transforming growth factor beta 1 multiple interactions ISO Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TGFB1 mRNA] CTD PMID:11306436 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922 		JBrowse link
G TH tyrosine hydroxylase increases expression ISO Deferoxamine results in increased expression of TH mRNA CTD PMID:9458725 NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815 		JBrowse link
G TLR4 toll like receptor 4 decreases expression EXP Deferoxamine results in decreased expression of TLR4 protein CTD PMID:24170104 NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735 		JBrowse link
G TNF tumor necrosis factor multiple interactions
increases response to substance
decreases expression
decreases activity		 EXP
ISO		 [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNF mRNA; Deferoxamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; ferrous sulfate inhibits the reaction [Deferoxamine results in decreased activity of TNF protein]
Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of TNF protein]
Deferoxamine results in increased susceptibility to TNF protein
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of TNF protein]; Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Deferoxamine]
Deferoxamine results in decreased expression of TNF mRNA		 CTD PMID:7532384 PMID:7539275 PMID:9851740 PMID:10486238 PMID:12633744 More... NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G TNFAIP6 TNF alpha induced protein 6 decreases expression EXP Deferoxamine results in decreased expression of TNFAIP6 mRNA CTD PMID:32816093 NCBI chr 2:151,357,592...151,381,340
Ensembl chr 2:151,357,592...151,380,046 		JBrowse link
G TNFRSF11A TNF receptor superfamily member 11a decreases expression ISO Deferoxamine results in decreased expression of TNFRSF11A mRNA CTD PMID:31238089 NCBI chr18:62,325,310...62,391,288
Ensembl chr18:62,325,287...62,391,288 		JBrowse link
G TNFSF10 TNF superfamily member 10 multiple interactions EXP [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA] CTD PMID:35690295 NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475 		JBrowse link
G TNFSF11 TNF superfamily member 11 multiple interactions ISO [Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK1 protein; [Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK3 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein] CTD PMID:31238089 NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013 		JBrowse link
G TP53 tumor protein p53 multiple interactions
increases expression
decreases response to substance		 EXP
ISO		 [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA]; Deferoxamine inhibits the reaction [sodium bichromate results in increased expression of TP53 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]; TP53 protein affects the reaction [Deferoxamine results in increased expression of BAX protein]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of TP53 mRNA]
Deferoxamine results in increased expression of TP53 protein
TP53 protein results in decreased susceptibility to Deferoxamine		 CTD PMID:10942736 PMID:16357363 PMID:16527254 PMID:23483119 PMID:33962019 More... NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 		JBrowse link
G TPD52L1 TPD52 like 1 decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of TPD52L1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of TPD52L1 protein]		 CTD PMID:19515424 NCBI chr 6:125,153,773...125,264,407
Ensembl chr 6:125,119,049...125,264,407 		JBrowse link
G TPI1 triosephosphate isomerase 1 increases expression ISO Deferoxamine results in increased expression of TPI1 mRNA CTD PMID:14762718 NCBI chr12:6,867,420...6,870,948
Ensembl chr12:6,867,119...6,870,948 		JBrowse link
G TRAP1 TNF receptor associated protein 1 decreases expression
multiple interactions		 EXP Deferoxamine results in decreased expression of TRAP1 mRNA; Deferoxamine results in decreased expression of TRAP1 protein
TRAP1 protein inhibits the reaction [Deferoxamine results in increased expression of SOD2 protein]		 CTD PMID:16927372 NCBI chr16:3,658,037...3,717,524
Ensembl chr16:3,651,639...3,717,553 		JBrowse link
G TUBB3 tubulin beta 3 class III increases expression ISO Deferoxamine results in increased expression of TUBB3 mRNA CTD PMID:16772336 NCBI chr16:89,921,925...89,936,097
Ensembl chr16:89,921,392...89,938,761 		JBrowse link
G UCP2 uncoupling protein 2 decreases expression EXP Deferoxamine results in decreased expression of UCP2 mRNA CTD PMID:12032628 NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843 		JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions EXP
ISO		 [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 protein]		 CTD PMID:12633744 PMID:30431687 NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045 		JBrowse link
G VDAC2 voltage dependent anion channel 2 multiple interactions
decreases expression		 EXP ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of VDAC2 protein]
Deferoxamine results in decreased expression of VDAC2 protein		 CTD PMID:19515424 NCBI chr10:75,210,170...75,231,448
Ensembl chr10:75,210,154...75,231,448 		JBrowse link
G VDR vitamin D receptor increases expression EXP Deferoxamine results in increased expression of VDR mRNA CTD PMID:20368581 NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048 		JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions
increases expression
increases secretion		 ISO
EXP		 Deferoxamine inhibits the reaction [LCN2 protein results in decreased secretion of VEGFA protein]
Deferoxamine results in increased expression of VEGFA mRNA
Deferoxamine results in increased expression of VEGFA mRNA; Deferoxamine results in increased expression of VEGFA protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA; Deferoxamine promotes the reaction [[HIF1A protein binds to VEGFA promoter] which results in increased expression of VEGFA mRNA]; Deferoxamine promotes the reaction [Potassium Dichromate results in increased expression of VEGFA protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA]
Deferoxamine results in increased secretion of VEGFA protein		 CTD PMID:10613739 PMID:12213806 PMID:15075239 PMID:16227210 PMID:17114340 More... NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
G VHL von Hippel-Lindau tumor suppressor multiple interactions EXP VHL protein mutant form affects the reaction [Deferoxamine results in decreased susceptibility to Hydrogen Peroxide] CTD PMID:18515279 NCBI chr 3:10,141,778...10,153,667
Ensembl chr 3:10,141,778...10,153,667 		JBrowse link
G WT1 WT1 transcription factor multiple interactions EXP [cobaltous chloride co-treated with Deferoxamine] results in increased expression of WT1 mRNA CTD PMID:12738801 NCBI chr11:32,387,775...32,435,539
Ensembl chr11:32,387,775...32,435,564 		JBrowse link
G XBP1 X-box binding protein 1 multiple interactions EXP Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of XBP1 protein] CTD PMID:32283200 NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26046
    role 25962
      biological role 25941
        inhibitor 22534
          ferroptosis inhibitor 7914
            desferrioxamine B 268
              desferrioxamine B mesylate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 26046
    subatomic particle 26021
      composite particle 26021
        hadron 26021
          baryon 26021
            nucleon 26021
              atomic nucleus 26021
                atom 26021
                  main group element atom 25846
                    p-block element atom 25846
                      carbon group element atom 25443
                        carbon atom 25401
                          organic molecular entity 25401
                            heteroorganic entity 24779
                              organochalcogen compound 24391
                                organooxygen compound 24069
                                  carbon oxoacid 22771
                                    carboxylic acid 22751
                                      carboacyl group 20074
                                        univalent carboacyl group 20074
                                          carbamoyl group 19588
                                            carboxamide 19588
                                              hydroxamic acid 6718
                                                desferrioxamine 268
                                                  acyclic desferrioxamine 268
                                                    desferrioxamine B 268
                                                      desferrioxamine B mesylate 0
paths to the root